The news of RBC Capital maintaining a Sector Perform rating on Regeneron Pharmaceuticals and raising the price target from $811 to $816 indicates a neutral outlook for the stock. The price target increase is relatively small, and the rating remains unchanged, suggesting that the analyst does not expect significant short-term price movement.